New antibody drug enters human trials for Tough-to-Treat cancers

NCT ID NCT05267626

Summary

This is the first study in people to test a new drug called AU-007 for advanced cancers that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug shows early signs of helping. It will be tested alone and in combination with other immune-boosting drugs in patients who have run out of standard treatment options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Austin Health

    RECRUITING

    Heidelberg, Victoria, 3084, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Carolina Biooncology Institute

    RECRUITING

    Huntersville, North Carolina, 28078, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030-4000, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Minnesota Oncology and Hematology PA

    RECRUITING

    Minneapolis, Minnesota, 55404-4526, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Monash Health

    RECRUITING

    Clayton, Victoria, 3168, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peninsula & South Eastern Haematology and Oncology Group

    RECRUITING

    Frankston, Victoria, 3199, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START Midwest

    RECRUITING

    Grand Rapids, Michigan, 49503-2563, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START South Texas Accelerated Research Therapeutics

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203-1619, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Southern Oncology Clinical Research Unit

    RECRUITING

    Bedford Park, South Australia, 5042, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Southside Cancer Care Centre

    RECRUITING

    Miranda, New South Wales, 2228, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sunshine Hospital

    RECRUITING

    Saint Albans, Victoria, 3021, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sylvester Comprehensive Cancer Center - Miami

    RECRUITING

    Miami, Florida, 33136-1002, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Texas Oncology (Balcones) - SCRI

    RECRUITING

    Austin, Texas, 78731-4214, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Alfred Hospital

    RECRUITING

    Melbourne, Victoria, 3004, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Utah - Huntsman Cancer Institute

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Washington University

    RECRUITING

    St Louis, Missouri, 63110-1010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.